Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies

BACKGROUND: Bevacizumab (BV) plus paclitaxel (PTX) is a treatment option in patients with HER2-negative metastatic breast cancer (mBC). We conducted an international pooled analysis with individual patient data to evaluate the effectiveness of BV + PTX as a first-line treatment for HER2-negative mBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Yutaka, Yamashiro, Hiroyasu, Schneeweiss, Andreas, Müller, Volkmar, Gluz, Oleg, Klare, Peter, Aktas, Bahriye, Magdolna, Dank, Büdi, László, Pikó, Béla, Mangel, László, Toi, Masakazu, Morita, Satoshi, Ohno, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813142/
https://www.ncbi.nlm.nih.gov/pubmed/36057014
http://dx.doi.org/10.1007/s12282-022-01399-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813142/
https://www.ncbi.nlm.nih.gov/pubmed/36057014
http://dx.doi.org/10.1007/s12282-022-01399-1

Ejemplares similares